Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients
Our results show that the threshold for methylation detection with the MS-MLPA method determined here is useful from a diagnostic perspective because it allows the stratification of patients who will benefit from specific treatment protocols, including temozolomide. Detailed analysis of the MGMT gene promoter enables the more-precise and personalized treatment of patients with glioblastoma.
Authors
- Dora Konečná
- David Netuka (ORCID: https://orcid.org/0000-0001-8609-4789)
- Halka Lhotská (ORCID: https://orcid.org/0000-0003-1767-395X)
- Karla Svobodová (ORCID: https://orcid.org/0000-0001-6757-1332)
- Jiří Soukup
- Filip Kramář (ORCID: https://orcid.org/0000-0003-0833-2360)
- Hana Cechova (ORCID: https://orcid.org/0000-0003-0539-8575)
- Tatiana Aghová (ORCID: https://orcid.org/0000-0002-4184-4678)
- Zuzana Zemanová (ORCID: https://orcid.org/0000-0002-7538-6601)
- Libuše Lizcová (ORCID: https://orcid.org/0000-0003-3934-3839)
- Karolina Janečkova
- Jaromir Macoun
- Lucie Hodanova
Institutions
- Charles University (CZ)
- Institute of Haematology and Blood Transfusion (CZ)
- Military University Hospital Prague (CZ)
- University Hospital Hradec Králové (CZ)
- General University Hospital in Prague (CZ)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1186/s13148-025-01822-2
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Ministerstvo Zdravotnictví Ceské Republiky
- Agentura Pro Zdravotnický Výzkum České Republiky
- Všeobecná Fakultní Nemocnice v Praze